Melinda HalaszGroup Leader
Laura MaugeriPh.D. Student
About the Group
What We Do
Malignancies arising in children are rare; and differ from cancers developing in adults. However, treatment regimens for children often consist of drugs used to treat adult cancers; and current therapies are associated with long-term side effects in children. Therefore, my group aims to identify less toxic and better personalised therapies for children with cancer. In particular, we focus on highly aggressive childhood cancers which are driven by the ‘undruggable’ MYCN or MYC transcription factors, such as neuroblastoma (NB) and Burkitt’s lymphoma (BL), respectively. NB originates from the sympathetic nervous system; while BL is a non-Hodgkin lymphoma which is endemic in Equatorial Africa. Our aim is to better understand the mechanistic role of MYC and MYCN in childhood cancers to identify novel therapies for children with MYC or MYCN-driven malignancies by using -omics and systems biology approaches.
Join our team
To find out more about our research, to collaborate on a project or if you are interested in postdoc, PhD or internship opportunities, contact firstname.lastname@example.org.
For a complete list see Google Scholar
Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling
Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN, Kolch W. Nature Cell Biology. 2014; 16(7):673-684.
The dynamic control of signal transduction networks in cancer cells
Kolch W, Halasz M, Granovskaya M, Kholodenko B. Nature Reviews Cancer. 2015; 15(9):515-527.
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients
Fey D, Halasz M, Dreidax D, Kennedy SP, Hastings JF, Rauch N, Munoz AG, Pilkington R, Fischer M, Westermann F, Kolch W, Kholodenko BN, Croucher DR. Science Signaling. 2015; 8(408):ra130.
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
Duffy DJ*, Krstic A*, Halasz M*, Schwarzl T*, Fey D, Iljin K, Mehta JP; Killick K; Whilde J; Turriziani B, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W. Oncotarget. 2015; 6(41):43182-43201.
Integrating network reconstruction with mechanistic modelling to predict cancer therapies
Halasz M, Kholodenko BN, Kolch W, Santra T. Science Signaling. 2016; 9(455):ra114.
Wnt signalling is a bi-directional vulnerability of cancer cells
Duffy DJ, Krstic A, Schwarzl T, Halasz M, Iijin K, Fey D, Haley B, Whilde J, Haapa-Paananen S, Fey V, Fischer M, Westermann F, Henrich KO, Bannert S, Higgins DG, Kolch W. Oncotarget. 2016; 7(37):60310-60331.
Retinoic acid and TGFβ signalling cooperate to overcome MYCN-induced retinoid resistance
Duffy DJ, Krstic A, Halasz M, Schwarzl T, Konietzny A, Iljin K, Higgins DG, Kolch W. Genome Medicine. 2017; 9(1):15.
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
Radic-Sarikas B*, Halasz M*, Huber KVM, Winter GE, Tsafou KP, Papamarkou T, Brunak S, Kolch W, Superti-Furga G. Scientific Reports. 2017; 7(1):3091.